Nov. 14 at 3:17 PM
$PRGO sounds ver bad for us bagholders ⚠️ Factors suggesting overvaluation or elevated risk
The company shows negative or very low profit levels: for example, return on equity (ROE) is negative or very low.
A DCF analysis places the fair value at around
$4.51 – compared to a current price near ~
$15, this implies ~70% downside risk.
Another valuation method (“Peter Lynch formula”) yields an even lower fair value (-
$2.92), which reflects the issue of negative earnings.
Forward-looking indicators show challenges: weak or declining organic revenue growth, margin pressure, etc.
The business model includes risk factors — brand dependency, private-label competition, regulatory pressure in OTC markets, and strong competitors.
